Dr. Konstantin H. Dragnev
Claim this profileDartmouth Hitchcock Medical Center
Area of expertise
Lung Cancer
Konstantin H. Dragnev has run 12 trials for Lung Cancer. Some of their research focus areas include:
Non-Small Cell Lung Cancer
Konstantin H. Dragnev has run 7 trials for Non-Small Cell Lung Cancer. Some of their research focus areas include:
Affiliated Hospitals
Dartmouth-Hitchcock Medical Center
Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
Clinical Trials Konstantin H. Dragnev is currently running
Multiple Targeted Therapies
for Meningioma
This trial studies four drugs to treat patients with worsening meningioma. These drugs work by blocking enzymes that the tumor cells need to grow. The trial focuses on patients whose tumors have specific genetic mutations.
Recruiting
1 award
Phase 2
10 criteria
Lomustine + Standard Therapy
for Glioblastoma
This phase III trial compares the effect of adding lomustine to standard chemotherapy with temozolomide and radiation therapy versus temozolomide and radiation therapy alone in shrinking or stabilizing newly diagnosed MGMT methylated glioblastoma. MGMT methylated tumors are more likely to respond to temozolomide chemotherapy. Temozolomide is in a class of medications called alkylating agents. It works by damaging the cell's DNA and may kill tumor cells and slow down or stop tumor growth. Lomustine is a chemotherapy drug and in a class of medications called alkylating agents. It damages the cell's DNA and may kill tumor cells. Radiation therapy uses high energy x-ray photons to kill tumor cells and shrink tumors. Adding lomustine to standard chemotherapy with temozolomide and radiation therapy may shrink or stabilize glioblastoma.
Recruiting
2 awards
Phase 3
4 criteria
More about Konstantin H. Dragnev
Clinical Trial Related
6 years of experience running clinical trials · Led 16 trials as a Principal Investigator · 7 Active Clinical Trials
Treatments Konstantin H. Dragnev has experience with
- Pembrolizumab
- Carboplatin
- Pemetrexed
- Capivasertib
- Vismodegib
- Temozolomide
Breakdown of trials Konstantin H. Dragnev has run
Lung Cancer
Non-Small Cell Lung Cancer
Pancreatic Cancer
Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Konstantin H. Dragnev specialize in?
Konstantin H. Dragnev focuses on Lung Cancer and Non-Small Cell Lung Cancer. In particular, much of their work with Lung Cancer has involved Stage IV patients, or patients who are Stage III.
Is Konstantin H. Dragnev currently recruiting for clinical trials?
Yes, Konstantin H. Dragnev is currently recruiting for 7 clinical trials in Lebanon New Hampshire. If you're interested in participating, you should apply.
Are there any treatments that Konstantin H. Dragnev has studied deeply?
Yes, Konstantin H. Dragnev has studied treatments such as Pembrolizumab, Carboplatin, Pemetrexed.
What is the best way to schedule an appointment with Konstantin H. Dragnev?
Apply for one of the trials that Konstantin H. Dragnev is conducting.
What is the office address of Konstantin H. Dragnev?
The office of Konstantin H. Dragnev is located at: Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire 03756 United States. This is the address for their practice at the Dartmouth Hitchcock Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.